Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Respiratory Tract Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Neoplasm Metastasis 1Liposarcoma 1Colorectal Neoplasms 1Advanced Non-small Cell Lung Cancer (NSCLC) 1Advanced Cancer 1

Interventions

entinostat 3efatutazone 2Erlotinib Hydrochloride 2Carboplatin 2sotorasib 1pralsetinib 1pembrolizumab 1osimertinib 1ficlatuzumab 1exemestane 1durvalumab 1cobimetinib 1camrelizumab 1Tyrosine Kinase Inhibitors 1Radiosurgery 1Pemetrexed 1Paclitaxel 1Gefitinib 1Dasatinib 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Respiratory Tract Neoplasms × efatutazone × Clear all
NCT01199068 2021-05-13

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Daiichi Sankyo

Phase 1 Completed
15 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Respiratory Tract Neoplasms

NCT01199055 2020-07-07

CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Daiichi Sankyo

Phase 1 Completed
16 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Respiratory Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡